Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.32 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | MANBA | O00462 | 1/20 | 0.32 |
| ▸ | IDUA | P35475 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | GUSB | P08236 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2931003 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL813413 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL21698544 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL4444890 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL468717 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL2466054 | 1.00 | LMNA (0.35) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL15858 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL6669482 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL592850 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA | |
| SCHEMBL15630 | 0.95 | LMNA (0.40) | LMNAGBA1DNMT1CTDSP1MANBA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9909129-B2 | Biosynthetic pathways and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-03-06 | — | — | US | claimed |
| US-20150337342-A1 | BIOSYNTHETIC PATHWAYS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-11-26 | — | — | US | claimed |
| WO-2014100173-A1 | BIOSYNTHETIC PATHWAYS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-26 | — | — | WO | claimed |
| EP-1976382-B1 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES | IDENIX PHARMACEUTICALS INC (US) | 2013-04-24 | — | — | EP | claimed |
| US-7781576-B2 | Process for preparing a synthetic intermediate for preparation of branched nucleosides | IDENIX PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | claimed |
| EP-1976382-A2 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES | IDENIX Pharmaceuticals, Inc. (US) | 2008-10-08 | — | — | EP | claimed |
| US-20070203334-A1 | contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone with a fluorinating agent under anhydrous conditions and converting the precursor into a protected 2-deoxy-2-halo-2-C-disubstituted ribono-1,5-lactone | IDENIX PHARMACEUTICALS LLC | 2007-08-30 | — | — | US | claimed |
| WO-2007075876-A2 | PROCESS FOR PREPARING A SYNTHETIC INTERMEDIATE FOR PREPARATION OF BRANCHED NUCLEOSIDES | IDENIX PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | claimed |
| EP-0631569-B1 | PRODUCTION OF XYLITOL | AMYLUM NV (BE) | 1997-06-18 | — | — | EP | claimed |
| US-5563303-A | Production of xylitol | AMYLUM, N.V. (BE) | 1996-10-08 | — | — | US | claimed |
| EP-0631569-A1 | PRODUCTION OF XYLITOL. | AMYLUM NV (BE) | 1995-01-04 | — | — | EP | claimed |
| WO-1993019030-A1 | PRODUCTION OF XYLITOL | AMYLUM, N.V. (BE) | 1993-09-30 | — | — | WO | claimed |
| US-20180080032-A1 | BIOSYNTHETIC PATHWAYS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2018-03-22 | — | — | US | disclosed |
| US-9909129-B2 | Biosynthetic pathways and methods | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2018-03-06 | — | — | US | disclosed |
| US-20150337342-A1 | BIOSYNTHETIC PATHWAYS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2015-11-26 | — | — | US | disclosed |
| WO-2014100173-A1 | BIOSYNTHETIC PATHWAYS AND METHODS | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2014-06-26 | — | — | WO | disclosed |
| US-20070203334-A1 | contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone with a fluorinating agent under anhydrous conditions and converting the precursor into a protected 2-deoxy-2-halo-2-C-disubstituted ribono-1,5-lactone | IDENIX PHARMACEUTICALS LLC | 2007-08-30 | — | — | US | disclosed |
| WO-2007045251-A2 | A COMPOSITION COMPRISING A COUPLED ENZYME SYSTEM | DANISCO A/S (DK) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045252-A2 | AN EDIBLE COMPOSITION | DANISCO A/S (DK) | 2007-04-26 | — | — | WO | disclosed |
| US-5563303-A | Production of xylitol | AMYLUM, N.V. (BE) | 1996-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203334-A1 | contacting a protected precursor 3,4-O-isopropylidene-2-C-substituted-D-arabinono-1,5-lactone with a fluorinating agent under anhydrous conditions and converting the precursor into a protected 2-deoxy-2-halo-2-C-disubstituted ribono-1,5-lactone | RPN1, DAD1, RPN2 | LMNA 554/4885GBA1 156/4885DNMT1 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.